What can we help you with today?
🔗 CustomizeMedical Overview of Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3
Sources citedCombined oxidative phosphorylation deficiency type 3 is an extremely rare clinically heterogenous disorder described in about 5 patients to date. Clinical signs included hypotonia, lactic acidosis, and hepatic insufficiency, with progressive encephalomyopathy or hypertrophic cardiomyopathy.
Classification & codes: GARD 0017035 · Orphanet ORPHA:168566 · OMIM 610505 · ICD-10 E88.8
Sources: GARD (NIH/NCATS), Orphanet · last reviewed 2026. Educational only — not medical advice.
News & Updates
ALYFTREK shows positive Phase 3 results in children ages 2–5
Vertex plans global regulatory submissions for this pediatric age group in the first half of 2026.
Airway clearance routines that actually work for teens
3 open trials match this profile
Locations in NC, FL and GA.
Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 Family Conference
Illustrative example event · location TBD
Care & management overview — Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3
Educational programming; see the cited sources on this hub.
Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 News & Developments
The latest Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 research, news and registered trials — live from public sources. Each link opens the source directly; nothing here is auto-summarized or invented.
Recruiting trials
View all →Find a Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 Specialist Near You
Sample results — illustrative only. A real version would search the NPPES provider registry and CFF-certified centers by actual distance from your ZIP.
Treatment & Daily Living
Medical care plus the everyday therapies and supports relevant to Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3. Treatment is individualized — ask your specialist about the medications, procedures and therapies. Browse medications →
Media Center
News, podcasts, books & research for Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 — real coverage, links out, never re-hosted.
Audience Guides
Plain-language guidance for the people around someone with Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 — how to understand it and talk about it. AI-generated for communication, not medical advice; always confirm specifics with a clinician.
Companies Developing Treatments
Biopharma companies with registered trials for Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 — from ClinicalTrials.gov. Informational, not an endorsement, and not every program is in trials.
Preferences only — saved to your account, never shared or sold. No PHI. Sources: GARD (NIH/NCATS), Orphanet.
Tools
Every institution behind the faculty, with their affiliated experts.
Plain-language tools
For clinicians, nonprofits & industry partners.
Translates any dense medical text — papers, lab results, visit notes, jargon — into plain language.
Live on tomekohealth.com — not a demo mock-up.
Research Collaboration & Matching
Live on tomekohealth.com — not a demo mock-up.
Mental Health Toolkit
Sources citedCoping strategies, how to find a a specialist therapist, and mental-health resources built for the ups and downs of living with Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 — for patients and caregivers alike.
Preferences only — saved to your account, never shared or sold. No PHI. Sources: GARD (NIH/NCATS), Orphanet.
Grand Rounds & Accredited Education
Open Questions
Ask the community →Anyone can ask. Sign in to answer. Peer support — not medical advice, and no PHI.
Survey
Reflect on how you are doing — anonymous, with only de-identified group averages shown.
Community & Support Groups
For people living with Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3. Peer support, not medical advice; no PHI.
For caregivers and family navigating Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3.
Recent From the Community
Certified Centers of Excellence
CFF networkCare centers and specialists for Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3, from Tomeko’s verified provider directory (CMS NPPES).
Representative CFF centers — the official CFF directory has the complete, current list.
Nonprofits & Foundations
Grants & Financial Help
Representative programs — illustrative only. Eligibility and availability vary; not a guarantee of assistance.
Patient & Family Guides
Sources citedAn annual snapshot of Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3 research, treatment access and outcomes, written in plain language for patients and families.
Practical starting points and things to plan for in the first year after diagnosis.
Step-by-step guidance, what to expect, and a sample daily routine.
Disclosure, accommodations, insurance transitions and workplace planning for teens and young adults with Fatal Mitochondrial Disease Due To Combined Oxidative Phosphorylation Defect Type 3.
Sources: GARD (NIH/NCATS), Orphanet · last reviewed 2026. Educational only — not medical advice.